Valerija Kovač
Research Subjects
Valerija Kovač has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Vladka Čurin Šerbec
Department for Production of Diagnostic Reagents and Research, Blood Transfusion Centre of Slovenia, Šlajmerjeva 6, 1000 Ljubljana, Slovenia
5 shared publications - Ana Kolenc
Slovenian Institute for Transfusion Medicine, Šlajmerjeva 6, SI-1000 Ljubljana, Slovenia
1 shared publication Blaž Zupančič
Slovenian NMR Centre, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia
1 shared publicationGregor Ilc
Slovenian NMR Centre, National Institute of Chemistry, Hajdrihova 19, SI-1000 Ljubljana, Slovenia; EN-FIST Centre of Excellence, Dunajska 156, SI-1001 Ljubljana, Slovenia
1 shared publication- Gregor Majdic
Veterinary Faculty, University of Ljubljana
1 shared publication Iva Hafner-Bratkovič
Department of Synthetic Biology and Immunology, National Institute of Chemistry, Hajdrihova 19, SI-1000, Ljubljana, Slovenia; EN-FIST Centre of Excellence, Trg Osvobodilne fronte 13, 1000, Ljubljana, Slovenia
1 shared publication
Latest Publications
- Open Access
- 23 December 2025
- Published by Elsevier in Journal of Immunological Methods
- Vol. 547, 114024
Optimization of a versatile cell ELISA for detection of antibodies against membrane protein BCMA
- 23 December 2025
- Published by Elsevier in Journal of Immunological Methods
- Vol. 547, 114024
Open AccessOptimization of a versatile cell ELISA for detection of antibodies against membrane protein BCMA
- Open Access
- 28 August 2024
- Published by Elsevier in Journal of Immunological Methods
- Vol. 534, 113747
Optimizing the method for expressing human monoclonal antibodies from a single peripheral blood cell from vaccinated donors
- 28 August 2024
- Published by Elsevier in Journal of Immunological Methods
- Vol. 534, 113747
Open AccessOptimizing the method for expressing human monoclonal antibodies from a single peripheral blood cell from vaccinated donors
- Open Access
- 22 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1232
Prion Protein: The Molecule of Many Forms and Faces
Cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored protein most abundantly found in the outer membrane of neurons. Due to structural characteristics (a flexible tail and structured core), PrPC interacts with a wide range of partners. Although PrPC has been proposed to be involved in many physiological functions, only peripheral nerve myelination homeostasis has been confirmed as a bona fide function thus far. PrPC misfolding causes prion diseases and PrPC has been shown to mediate β-rich oligomer-induced neurotoxicity in Alzheimer’s and Parkinson’s disease as well as neuroprotection in ischemia. Upon proteolytic cleavage, PrPC is transformed into released and attached forms of PrP that can, depending on the contained structural characteristics of PrPC, display protective or toxic properties. In this review, we will outline prion protein and prion protein fragment properties as well as overview their involvement with interacting partners and signal pathways in myelination, neuroprotection and neurodegenerative diseases.
- 22 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (3) , 1232
Open AccessPrion Protein: The Molecule of Many Forms and Faces
Cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored protein most abundantly found in the outer membrane of neurons. Due to structural characteristics (a flexible tail and structured core), PrPC interacts with a wide range of partners. Although PrPC has been proposed to be involved in many physiological functions, only peripheral nerve myelination homeostasis has been confirmed as a bona fide function thus far. PrPC misfolding causes prion diseases and PrPC has been shown to mediate β-rich oligomer-induced neurotoxicity in Alzheimer’s and Parkinson’s disease as well as neuroprotection in ischemia. Upon proteolytic cleavage, PrPC is transformed into released and attached forms of PrP that can, depending on the contained structural characteristics of PrPC, display protective or toxic properties. In this review, we will outline prion protein and prion protein fragment properties as well as overview their involvement with interacting partners and signal pathways in myelination, neuroprotection and neurodegenerative diseases.
- Open Access
- 13 January 2021
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 7
Comparison of Canine and Feline Adipose-Derived Mesenchymal Stem Cells/Medicinal Signaling Cells With Regard to Cell Surface Marker Expression, Viability, Proliferation, and Differentiation Potential
Remarkable immunomodulatory abilities of mesenchymal stem cells, also called multipotent mesenchymal stromal cells or medicinal signaling cells (MSCs), have entailed significant advances in veterinary regenerative medicine in recent years. Despite positive outcomes from MSC therapies in various diseases in dogs and cats, differences in MSC characteristics between small animal veterinary patients are not well-known. We performed a comparative study of cells' surface marker expression, viability, proliferation, and differentiation capacity of adipose-derived MSCs (ADMSCs) from dogs and domestic cats. The same growth media and methods were used to isolate, characterize, and culture canine and feline ADMSCs. Adipose tissue was collected from 11 dogs and 8 cats of both sexes. The expression of surface markers CD44, CD90, and CD34 was detected by flow cytometry. Viability at passage 3 was measured with the hemocytometer and compared to the viability measured by flow cytometry after 1 day of handling. The proliferation potential of MSCs was measured by calculating cell doubling and cell doubling time from second to eighth passage. Differentiation potential was determined at early and late passages by inducing cells toward adipogenic, osteogenic, and chondrogenic differentiation using commercial media. Our study shows that the percentage of CD44+CD90+ and CD34−/− cells is higher in cells from dogs than in cells from cats. The viability of cells measured by two different methods at passage 3 differed between the species, and finally, canine ADMSCs possess greater proliferation and differentiation potential in comparison to the feline ADMSCs.
- 13 January 2021
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 7
Open AccessComparison of Canine and Feline Adipose-Derived Mesenchymal Stem Cells/Medicinal Signaling Cells With Regard to Cell Surface Marker Expression, Viability, Proliferation, and Differentiation Potential
Remarkable immunomodulatory abilities of mesenchymal stem cells, also called multipotent mesenchymal stromal cells or medicinal signaling cells (MSCs), have entailed significant advances in veterinary regenerative medicine in recent years. Despite positive outcomes from MSC therapies in various diseases in dogs and cats, differences in MSC characteristics between small animal veterinary patients are not well-known. We performed a comparative study of cells' surface marker expression, viability, proliferation, and differentiation capacity of adipose-derived MSCs (ADMSCs) from dogs and domestic cats. The same growth media and methods were used to isolate, characterize, and culture canine and feline ADMSCs. Adipose tissue was collected from 11 dogs and 8 cats of both sexes. The expression of surface markers CD44, CD90, and CD34 was detected by flow cytometry. Viability at passage 3 was measured with the hemocytometer and compared to the viability measured by flow cytometry after 1 day of handling. The proliferation potential of MSCs was measured by calculating cell doubling and cell doubling time from second to eighth passage. Differentiation potential was determined at early and late passages by inducing cells toward adipogenic, osteogenic, and chondrogenic differentiation using commercial media. Our study shows that the percentage of CD44+CD90+ and CD34−/− cells is higher in cells from dogs than in cells from cats. The viability of cells measured by two different methods at passage 3 differed between the species, and finally, canine ADMSCs possess greater proliferation and differentiation potential in comparison to the feline ADMSCs.
- Open Access
- 1 January 2018
- Published by SAGE Publications in Biomarker Insights
- Vol. 13
Prion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases
Prion protein (PrP) is a biomolecule that is involved in neuronal signaling, myelinization, and the development of neurodegenerative diseases. In the cell, PrP is shed by the ADAM10 protease. This process generates PrP molecules that lack glycophosphatidylinositol anchor, and these molecules incorporate into toxic aggregates and neutralize toxic oligomers. Due to this dual role, these molecules are important biomarkers for neurodegenerative diseases. In this review, we present shed PrP as a potential biomarker, with a focus on PrP226*, which may be the main biomarker for predicting neurodegenerative diseases in humans.
- 1 January 2018
- Published by SAGE Publications in Biomarker Insights
- Vol. 13
Open AccessPrion Proteins Without the Glycophosphatidylinositol Anchor: Potential Biomarkers in Neurodegenerative Diseases
Prion protein (PrP) is a biomolecule that is involved in neuronal signaling, myelinization, and the development of neurodegenerative diseases. In the cell, PrP is shed by the ADAM10 protease. This process generates PrP molecules that lack glycophosphatidylinositol anchor, and these molecules incorporate into toxic aggregates and neutralize toxic oligomers. Due to this dual role, these molecules are important biomarkers for neurodegenerative diseases. In this review, we present shed PrP as a potential biomarker, with a focus on PrP226*, which may be the main biomarker for predicting neurodegenerative diseases in humans.
- Open Access
- 1 February 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 484 (1) , 45-50
Truncated prion protein PrP226* - A structural view on its role in amyloid disease
- 1 February 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 484 (1) , 45-50
Open AccessTruncated prion protein PrP226* - A structural view on its role in amyloid disease
- Open Access
- 1 December 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 481 (1-2) , 1-6
Anchorless forms of prion protein – Impact of truncation on structure destabilization and prion protein conversion
- 1 December 2016
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 481 (1-2) , 1-6
Open AccessAnchorless forms of prion protein – Impact of truncation on structure destabilization and prion protein conversion